Sunday 18 October 2026 Export LENZ’s income statement to Excel — free account

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million. In the quarter to June 2026, revenue grew 9.72%, EPS fell 92.5% and free cash flow fell 229.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.27 0.30 −8.40%

Follow LENZ

Alert me

Market cap: $112.2M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: 0.00%
F-score: n/a
Altman Z: 11.98
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.65

Total sells 0.26

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	—	—	—	3	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.40%

Capital & Financial Ratios $m

Market Cap 112.17

Revenue 21.48

Net Income (126.00)

Free Cash Flow (114.42)

Net Debt (220.00)

Current Ratio 13.55

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.56)

P/S ratio 4.78

P/B ratio 0.47

Past 5Y EPS Growth —

This Y EPS Growth (45.35%)

Next Y EPS Growth 37.82%

Next Y revenue growth (10.99%)

Next 5Y EPS Growth 29.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 31.42%

10-year low 10-year high

EV/FCF against its own 10 years 23.67%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2025	Powerpack
2024	1.03	1.03
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	66	209	292	220
Receivables	—	—	0	0
Inventory	—	—	3	4
Other	—	—	—	—
	67	212	301	233

	2023	2024	2025	Q'26
Payables	6	4	4	7
ST’ Debt	—	—	—	—
Other	—	—	—	—
	19	10	21	17

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(1.36%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	5	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(34)	(39)	—	—	—
’25	(16)	(12)	(9)	(33)	(69)
’24	(24)	(16)	(11)	(9)	(59)
’23	(13)	(14)	(13)	(21)	(60)
’22	(21)	(22)	(22)	(22)	(88)
’21	(8)	(14)	(15)	(16)	(53)
’20	0	(1)	(2)	(5)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(34)	(39)	—	—	—
’25	(16)	(12)	(9)	(33)	(70)
’24	(24)	(16)	(11)	(9)	(60)
’23	(13)	(14)	(13)	(21)	(60)
’22	(25)	(23)	(23)	(23)	(95)
’21	(8)	(15)	(19)	(17)	(59)
’20	0	(1)	(3)	(6)	(10)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.32)	(1.02)	—	—	—
’25	(0.53)	(0.53)	(0.59)	(1.16)	(2.85)
’24	(3.53)	(0.40)	(0.38)	(0.46)	(2.34)
’23	(6.49)	(6.79)	(9.62)	(12.07)	(35.72)
’22	(3.36)	(3.36)	(3.15)	(3.08)	(12.88)
’21	(40.27)	(24.14)	(1.96)	(2.45)	(17.14)
’20	0.00	(3.94)	(7.00)	—	(209.49)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	56.77	14.49	11.13	14.42	15.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	238.00	93.73	24.01	38.93	50.40
People
People	Employees	—	—	—	—	27	69	120	6	42	152
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.13
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	19
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	97.81
	EBT	—	—	—	0	(68)	(71)	(101)	(70)	(50)	(82)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(427.62)
	Net income	—	0	—	0	(68)	(71)	(101)	(70)	(50)	(82)
	Depreciation	—	—	—	—	0	1	1	(1)	0	0
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.66
	Earnings	—	—	—	0.00	(209.49)	(17.14)	(12.88)	(35.72)	(2.34)	(2.85)
	Cash flow	—	—	—	0.00	(26.72)	(12.79)	(11.22)	(30.82)	(2.79)	(2.40)
	Capex	—	—	—	0.00	(4.73)	(1.39)	(0.84)	(0.02)	(0.02)	(0.03)
	Free cash flow	—	—	—	0.00	(31.45)	(14.18)	(12.06)	(30.84)	(2.81)	(2.43)
	Book value	—	—	—	0.00	(200.39)	92.93	37.79	(47.33)	9.59	9.87
	Shares, m	—	—	—	0	0	4	8	2	21	29
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	0.00
	P/S	—	—	—	—	—	—	—	—	—	0.00
	P/B	—	—	—	—	—	—	—	—	—	1.62
	EV/Sales	—	—	—	—	—	—	—	—	—	0.00
	EV/FCF	—	—	—	—	—	—	—	—	—	(2.44)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	0	(9)	(53)	(88)	(60)	(59)	(69)
	Capex	—	—	—	—	(2)	(6)	(7)	0	0	(1)
	Free cash flow	—	—	—	0	(10)	(59)	(95)	(60)	(60)	(70)
Balance, $m
Balance, $m	Working capital	—	—	—	(2)	(11)	370	262	49	202	280
	Total debt	—	—	—	2	—	—	4	—	—	—
	Net debt	—	—	—	2	(20)	(377)	(268)	(66)	(209)	(292)
	Shareholders’ equity	—	—	—	(2)	(65)	384	296	(93)	204	284
Returns, %
Returns, %	ROA	—	—	—	(3,633.33)	(605.88)	(33.33)	(27.92)	(35.67)	(34.84)	(31.52)
	ROIC	—	—	—	0.00	0.00	(534.02)	(235.28)	0.00	0.00	0.00
	ROE	—	—	—	0.32	202.21	(44.41)	(29.71)	(68.74)	(89.37)	(33.63)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NERV Minerva Neurosciences, Inc	$115.6M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
ARMP Armata Pharmaceuticals, Inc.	$114.9M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)	Compare
ENGN enGene Therapeutics Inc	$114.6M	— (loss-making)	—	—	n/m	+28.07% (above 0%: growing)	—	0.00%	Compare
SEER Seer, Inc.	$113.0M	— (loss-making)	— (loss-making)	−23.43% (below 0%: shrinking)	n/m	+36.73% (above 0%: growing)	48.55%	(542.91%)	Compare
FHTX Foghorn Therapeutics Inc.	$112.2M	— (loss-making)	— (loss-making)	+112.68% (above 0%: growing)	n/m	+14.88% (above 0%: growing)	100.00%	(54.78%)	Compare
GNLX Genelux Corporation	$112.2M	— (loss-making)	— (loss-making)	—	n/m	−11.18% (below 0%: shrinking)	100.00%	0.00%	Compare
LENZ LENZ Therapeutics, Inc.	$112.2M	— (loss-making)	— (loss-making)	+9.72% (above 0%: growing)	n/m	−229.66% (below 0%: shrinking)	94.90%	(622.89%)
TNXP Tonix Pharmaceuticals Holding Corp.	$110.1M	— (loss-making)	— (loss-making)	+577.88% (above 0%: growing)	n/m	−178.84% (below 0%: shrinking)	94.81%	(314.05%)	Compare
VTVT vTv Therapeutics Inc.	$109.1M	— (loss-making)	— (loss-making)	+409,222.22% (above 0%: growing)	n/m	−124.59% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$112.6M	—	—	+112.68%	—	−14.58%	100.00%	(27.39%)

All 614 Biotechnology stocks →

LENZ Therapeutics, Inc. (LENZ) key facts

LENZ Therapeutics, Inc. (LENZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
As of October 16, 2026, LENZ traded at $3.27, a market capitalization of $112.2 million.
LENZ Therapeutics, Inc. does not currently pay a dividend.
Return on equity was −33.6% and debt-to-equity 0.00.
Its Altman Z-score is 11.98 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.